Racura Oncology (RAC) Short Interest
Racura Oncology (ASX:RAC) had 0.01% of shares reported as short positions as of 24 Aug 2026, representing 19,354 shares. Racura Oncology operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Racura Oncology
Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapeutics. Their lead asset, RCDS1 (E,E-bisantrene), targets G4-DNA & RNA binding to inhibit MYC, a key cancer growth regulator, and is being advanced in multiple oncology indications.
Short position
Racura Oncology (ASX:RAC) has 0.01% of its shares on issue reported as short positions as of 24 Aug 2026, or about 19,354 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. RAC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4RAC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Racura Oncology
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss RAC
Start a research thread or post the first pulse update